StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIFree Report) in a report published on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of Brainstorm Cell Therapeutics stock opened at $0.52 on Thursday. Brainstorm Cell Therapeutics has a 1-year low of $0.13 and a 1-year high of $3.34. The company has a market capitalization of $36.45 million, a PE ratio of -1.63 and a beta of 0.40. The business has a 50-day moving average of $0.51 and a 200-day moving average of $0.36.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. On average, equities analysts expect that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIFree Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Recommended Stories

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.